Fidelity's reduction below 5% removes any filing obligation for further changes, but the passive nature of the stake means no activist pressure. Monitor for any future 13D conversion if the investor's intent changes.
NRIX drugs
NRIX drug pipeline →- ▲ bexobrutideg 5/10 Phase 1a/b (pivotal Phase 2 underway; Phase 3 planned summer 2026)
- ● GS-6791 4/10 Phase 1
- ● NX-1607 4/10 Phase 1 (Phase 1a dose escalation complete; Phase 1b expansion planned)
- ● zelebrudomide 3/10 Phase 1
- ● NX-3911 2/10 Preclinical / IND-enabling — Phase 1 trial authorized (EU CTIS) but not yet recruiting
- All NRIX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $14.84entry
- T+1 · 11d ago +3.10%α +2.79% · $15.30
- T+5 · 5d ago +5.12%α +1.83% · $15.60
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
FMR LLC (Fidelity) filed an amended Schedule 13G disclosing a 4.2% passive stake in Nurix Therapeutics as of September 30, 2026, down from a prior position. The filing confirms Fidelity remains a significant passive holder but below the 5% threshold, with no intent to influence control.
Key Financial Metrics
Key Facts
- FMR LLC reported beneficial ownership of 4,350,596.42 shares of Nurix Therapeutics common stock as of September 30, 2026.
- The stake represents 4.2% of shares outstanding, below the 5% threshold.
- This is an amendment to a prior Schedule 13G filing, indicating a decrease from a previously larger position.
- FMR LLC certifies the shares were acquired and are held in the ordinary course of business with no intent to influence control.
- The filing is made jointly by FMR LLC and Abigail P. Johnson.
Financial Impact
FMR LLC holds 4,350,596 shares valued at approximately $183M based on market cap of $2.8B and 4.2% stake.
Risk Factors
- FMR LLC stake below 5% means no further public disclosure of position changes is required, reducing transparency.
- The reduction could signal reduced conviction, though as a passive index/asset manager it may reflect portfolio rebalancing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0000315066-26-002803 |
| Document: 0000315066-26-002803-index-headers.html | 0000315066-26-002803 |
| Document: 0000315066-26-002803-index.html | 0000315066-26-002803 |
| Document: 0000315066-26-002803.txt | 0000315066-26-002803 |
Track record
33 reports on NRIX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +53.71% at T+20 after the Jun 8, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $14.67 Now $14.73 +0.41% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.17 Now $14.73 −2.90% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.41 Now $14.73 −4.41% settles Dec 15
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Viewing Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $15.95 Now $14.73 −7.65% settles Dec 3
- Nov 3, 202613d ago 8-K Bearish 5/10 Entry $15.95 Now $14.73 +7.65% settles Dec 3
- Nov 2, 202614d ago Insider Cluster Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers